Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Report

Generic Pharmaceuticals Contract Manufacturing Market (2025 - 2030) Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, By Region, And Segment Forecasts

Market Segmentation

Generic Pharmaceuticals Contract Manufacturing Drug Type Outlook (Revenue, USD Million, 2018 - 2030)
- Branded Generics
- Unbranded Generics
Generic Pharmaceuticals Contract Manufacturing Product Outlook (Revenue, USD Million, 2018 - 2030)
- API
- Drug Product
Generic Pharmaceuticals Contract Manufacturing Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Parenteral
- Topical
- Others
Generic Pharmaceuticals Contract Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Immunology
- Antidiabetic
- Neurology
- Anticoagulants
- Cardiovascular
- Respiratory
- Pain
- HIV antivirals
- Others
Generic Pharmaceuticals Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Branded Generics
    - Unbranded Generics
  - North America Product Outlook (Revenue in USD Million, 2018 - 2030)
    - API
    - Drug Product
  - North America Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Topical
    - Others
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Immunology
    - Antidiabetic
    - Neurology
    - Anticoagulants
    - Cardiovascular
    - Respiratory
    - Pain
    - HIV antivirals
    - Others
  - U.S.
    - U.S. Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - U.S. Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - U.S. Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - U.S. Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Canada
    - Canada Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Canada Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Canada Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Canada Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Mexico
    - Mexico Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Mexico Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Mexico Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Mexico Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
- Europe
  - Europe Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Branded Generics
    - Unbranded Generics
  - Europe Product Outlook (Revenue in USD Million, 2018 - 2030)
    - API
    - Drug Product
  - Europe Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Topical
    - Others
  - Europe Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Immunology
    - Antidiabetic
    - Neurology
    - Anticoagulants
    - Cardiovascular
    - Respiratory
    - Pain
    - HIV antivirals
    - Others
  - UK
    - UK Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - UK Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - UK Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - UK Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Germany
    - Germany Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Germany Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Germany Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Germany Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - France
    - France Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - France Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - France Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - France Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Italy
    - Italy Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Italy Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Italy Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Italy Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Spain
    - Spain Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Spain Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Spain Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Spain Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Denmark
    - Denmark Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Denmark Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Denmark Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Denmark Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Sweden
    - Sweden Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Sweden Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Sweden Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Sweden Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Norway
    - Norway Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Norway Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Norway Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Norway Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
- Asia Pacific
  - Asia Pacific Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Branded Generics
    - Unbranded Generics
  - Asia Pacific Product Outlook (Revenue in USD Million, 2018 - 2030)
    - API
    - Drug Product
  - Asia Pacific Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Topical
    - Others
  - Asia Pacific Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Immunology
    - Antidiabetic
    - Neurology
    - Anticoagulants
    - Cardiovascular
    - Respiratory
    - Pain
    - HIV antivirals
    - Others
  - Japan
    - Japan Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Japan Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Japan Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Japan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - China
    - China Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - China Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - China Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - China Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - India
    - India Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - India Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - India Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - India Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Thailand
    - Thailand Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Thailand Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Thailand Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Thailand Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - South Korea
    - South Korea Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - South Korea Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - South Korea Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - South Korea Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Australia
    - Australia Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Australia Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Australia Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Australia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
- Latin America
  - Latin America Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Branded Generics
    - Unbranded Generics
  - Latin America Product Outlook (Revenue in USD Million, 2018 - 2030)
    - API
    - Drug Product
  - Latin America Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Topical
    - Others
  - Latin America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Immunology
    - Antidiabetic
    - Neurology
    - Anticoagulants
    - Cardiovascular
    - Respiratory
    - Pain
    - HIV antivirals
    - Others
  - Brazil
    - Brazil Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Brazil Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Brazil Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Brazil Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Argentina
    - Argentina Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Argentina Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Argentina Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Argentina Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
- Middle East and Africa
  - Middle East and Africa Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Branded Generics
    - Unbranded Generics
  - Middle East and Africa Product Outlook (Revenue in USD Million, 2018 - 2030)
    - API
    - Drug Product
  - Middle East and Africa Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Topical
    - Others
  - Middle East and Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Immunology
    - Antidiabetic
    - Neurology
    - Anticoagulants
    - Cardiovascular
    - Respiratory
    - Pain
    - HIV antivirals
    - Others
  - South Africa
    - South Africa Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - South Africa Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - South Africa Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - South Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Saudi Arabia
    - Saudi Arabia Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Saudi Arabia Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Saudi Arabia Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Saudi Arabia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - UAE
    - UAE Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - UAE Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - UAE Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - UAE Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others
  - Kuwait
    - Kuwait Drug Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Branded Generics
      - Unbranded Generics
    - Kuwait Product Outlook (Revenue in USD Million, 2018 - 2030)
      - API
      - Drug Product
    - Kuwait Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Topical
      - Others
    - Kuwait Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Immunology
      - Antidiabetic
      - Neurology
      - Anticoagulants
      - Cardiovascular
      - Respiratory
      - Pain
      - HIV antivirals
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments